# BO-112 With Pembrolizumab in Unresectable Malignant Melanoma

> **NCT04570332** · PHASE2 · COMPLETED · sponsor: **Highlight Therapeutics** · enrollment: 42 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** BO-112 plus pembrolizumab
- **PROCEDURE:** Tissue Biopsies

## Key facts

- **NCT ID:** NCT04570332
- **Lead sponsor:** Highlight Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-30
- **Primary completion:** 2023-10-03
- **Final completion:** 2024-11-04
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04570332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04570332, "BO-112 With Pembrolizumab in Unresectable Malignant Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04570332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*